A peritoneal dialysis regimen low in glucose and glucose degradation products results in increased cancer antigen 125 and peritoneal activation

Peritoneal Dialysis International

Volumn 32, Issue 3, 2012, Pages 305-315

  le Poole, Caatje Y ^a,b   Welten, Angelique G A ^a   ter Wee, Piet M ^a   Paauw, Nanne J ^a   Djorai, Amina N ^a   Valentijn, Rob M ^b   Beelen, Robert H J ^a   van den Born, Jacob ^a,c   van Ittersum, Frans J ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Red Cross Hospital Den Haag   (Netherlands)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Amino acids; Biocompatibility; CA125; CAPD; Clinical trial; Glucose; Glucose degradation products; Icodextrin; Mesothelial regeneration

Indexed keywords

BIOLOGICAL MARKER; CA 125 ANTIGEN; CD16 ANTIGEN; CREATININE; EXTRANEAL; FC RECEPTOR; FC RECEPTOR I; FC RECEPTOR IIA; GLUCOSE; GLUCOSE DEGRADATION PRODUCT; HYALURONIC ACID; INTERLEUKIN 6; INTERLEUKIN 8; MISCELLANEOUS DRUGS AND AGENTS; NUTRINEAL; PHYSIONEAL; UNCLASSIFIED DRUG; VASCULOTROPIN;

ALTERNATIVE MEDICINE; ARTICLE; CELL ACTIVATION; CELL ASSAY; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; CLINICAL INDICATOR; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; CONTROLLED STUDY; CROSSOVER PROCEDURE; HUMAN; INTERMETHOD COMPARISON; LEUKOCYTE COUNT; MESOTHELIUM CELL; MULTICENTER STUDY; NAUSEA; OUTCOME ASSESSMENT; PERITONITIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; SKIN ALLERGY; TREATMENT DURATION; UPREGULATION;

CA-125 ANTIGEN; CROSS-OVER STUDIES; DIALYSIS SOLUTIONS; GLUCOSE; HUMANS; LEUKOCYTE COUNT; PERITONEAL DIALYSIS; PERITONEUM; PROSPECTIVE STUDIES; SINGLE-BLIND METHOD;

EID: 84861682342     PISSN: 08968608     EISSN: 17184304     Source Type: Journal    
DOI: 10.3747/pdi.2010.00115     Document Type: Article

References (44)

1. Mutsaers SE. Mesothelial cells: their structure, function and role in serosal repair. Respirology 2002; 7:171-91.
2. Holmdahl L, Ivarsson ML. The role of cytokines, coagulation, and fibrinolysis in peritoneal tissue repair. Eur J Surg 1999; 165:1012-19.
3. Nagy JA, Jackman RW. Basic science and dialysis: response of the peritoneal membrane to injury. Semin Dial 1998; 11:42-8.
4. Morgan LW, Wieslander A, Davies M, Horiuchi T, Ohta Y, Beavis MJ, et al. Glucose degradation products (GDP) retard remesothelialization independently of d-glucose concentration. Kidney Int 2003; 64:1854-66.
5. Williams JD, Craig KJ, Topley N, Von Ruhland C, Fallon M, Newman GR, et al. Morphologic changes in the peritoneal membrane of patients with renal disease. J Am Soc Nephrol 2002; 13:470-9.
6. Zareie M, Hekking LH, Welten AG, Driesprong BA, Schadee-Eestermans IL, Faict D, et al. Contribution of lactate buffer, glucose and glucose degradation products to peritoneal injury in vivo. Nephrol Dial Transplant 2003; 18:2629-37.
7. Coles GA, Topley N. Long-term peritoneal membrane changes. Adv Ren Replace Ther 2000; 7:289-301.
8. Rippe B, Simonsen O, Heimbürger O, Christensson A, Haraldsson B, Stelin G, et al. Long-term clinical effects of a peritoneal dialysis fluid with less glucose degradation products. Kidney Int 2001; 59:348-57.
9. Williams JD, Topley N, Craig KJ, Mackenzie RK, Pischetsrieder M, Lage C, et al. The Euro-Balance Trial: the effect of a new biocompatible peritoneal dialysis fluid (Balance) on the peritoneal membrane. Kidney Int 2004; 66:408-18.
10. Jones S, Holmes CJ, Krediet RT, Mackenzie R, Faict D, Tranæus A, et al. Bicarbonate/lactate-based peritoneal dialysis solution increases cancer antigen 125 and decreases hyaluronic acid levels. Kidney Int 2001; 59:1529-38.
11. Visser CE, Brouwer-Steenbergen JJ, Betjes MG, Koomen GC, Beelen RH, Krediet RT. Cancer antigen 125: a bulk marker for the mesothelial mass in stable peritoneal dialysis patients. Nephrol Dial Transplant 1995; 10:64-9.
12. Szeto CC, Chow KM, Lam CW, Leung CB, Kwan BC, Chung KY, et al. Clinical biocompatibility of a neutral peritoneal dialysis solution with minimal glucose-degradation products-a 1-year randomized control trial. Nephrol Dial Transplant 2007; 22:552-9.
13. Hekking LH, Zareie M, Driesprong BA, Faict D, Welten AG, de Greeuw I, et al. Better preservation of peritoneal morphologic features and defense in rats after long-term exposure to a bicarbonate/lactate-buffered solution. J Am Soc Nephrol 2001; 12:2775-86.
14. Posthuma N, Verbrugh HA, Donker AJ, van Dorp W, Dekker HA, Peers EM, et al. Peritoneal kinetics and mesothelial markers in CCPD using icodextrin for daytime dwell for two years. Perit Dial Int 2000; 20:174-80.
15. Taylor GS, Patel V, Spencer S, Fluck RJ, McIntyre CW. Long-term use of 1.1% amino acid dialysis solution in hypoalbuminemic continuous ambulatory peritoneal dialysis patients. Clin Nephrol 2002; 58:445-50.
16. le Poole CY, van Ittersum FJ, Weijmer MC, Valentijn RM, ter Wee PM. Clinical effects of a peritoneal dialysis regimen low in glucose in new peritoneal dialysis patients: a randomized crossover study. Adv Perit Dial 2004; 20:170-6.
17. le Poole CY, Welten AG, Weijmer MC, Valentijn RM, van Ittersum FJ, ter Wee PM. Initiating CAPD with a regimen low in glucose and glucose degradation products, with icodextrin and amino acids (NEPP) is safe and efficacious. Perit Dial Int 2005; 25(Suppl 3):S64-8.
18. Twardowski ZJ, Nolph KD, Khanna R, Prowant BF, Ryan LP, Moore HL, et al. Peritoneal equilibration test. Perit Dial Int 1987; 7:138-47.
19. Betjes MG, Tuk CW, Struijk DG, Krediet RT, Arisz L, Hoefsmit EC, et al. Immuno-effector characteristics of peritoneal cells during CAPD treatment: a longitudinal study. Kidney Int 1993; 43:641-8.
20. Tekstra J, Visser CE, Tuk CW, Brouwer-Steenbergen JJ, Burger CW, Krediet RT, et al. Identification of the major chemokines that regulate cell influxes in peritoneal dialysis patients. J Am Soc Nephrol 1996; 7:2379-84.
21. Fosang AJ, Hey NJ, Carney SL, Hardingham TE. An ELISA plate-based assay for hyaluronan using biotinylated proteoglycan G1 domain (HA-binding region). Matrix 1990; 10:306-13.
22. Kumar-Singh S, Jacobs W, Dhaene K, Weyn B, Bogers J, Weyler J, et al. Syndecan-1 expression in malignant mesothelioma: correlation with cell differentiation, WT1 expression, and clinical outcome. J Pathol 1998; 186:300-5.
23. Gulyás M, Hjerpe A. Proteoglycans and WT1 as markers for distinguishing adenocarcinoma, epithelioid mesothelioma, and benign mesothelium. J Pathol 2003; 199:479-87.
24. Subramanian SV, Fitzgerald ML, Bernfield M. Regulated shedding of syndecan-1 and -4 ectodomains by thrombin and growth factor receptor activation. J Biol Chem 1997; 272:14713-20.
25. Fitzgerald ML, Wang Z, Park PW, Murphy G, Bernfield M. Shedding of syndecan-1 and -4 ectodomains is regulated by multiple signaling pathways and mediated by a TIMP-3-sensitive metalloproteinase. J Cell Biol 2000; 148:811-24.
26. Martis L, Patel M, Giertych J, Mongoven J, Taminne M, Perrier MA, et al. Aseptic peritonitis due to peptidoglycan contamination of pharmacopoeia standard dialysis solution. Lancet 2005; 365:588-94.
27. Boer WH, Vos PF, Fieren MW. Culture-negative peritonitis associated with the use of icodextrin-containing dialysate in twelve patients treated with peritoneal dialysis. Perit Dial Int 2003; 23:33-8.
28. Twisk JW. Longitudinal data analysis. A comparison between generalized estimating equations and random coefficient analysis. Eur J Epidemiol 2004; 19:769-76.
29. Johnson DW, Mudge DW, Blizzard S, Arndt M, O'Shea A, Watt R, et al. A comparison of peritoneal equilibration tests performed 1 and 4 weeks after PD commencement. Perit Dial Int 2004; 24:460-5.
30. Krediet RT. Dialysate cancer antigen 125 concentration as marker of peritoneal membrane status in patients treated with chronic peritoneal dialysis. Perit Dial Int 2001; 21:560-7.
31. Day RM, Mitchell TJ, Knight SC, Forbes A. Regulation of epithelial syndecan-1 expression by inflammatory cytokines. Cytokine 2003; 21:224-33.
32. Lai KN, Szeto CC, Lai KB, Lam CW, Chan DT, Leung JC. Increased production of hyaluronan by peritoneal cells and its significance in patients on CAPD. Am J Kidney Dis 1999; 33:318-24.
33. Yung S, Thomas GJ, Davies M. Induction of hyaluronan metabolism after mechanical injury of human peritoneal mesothelial cells in vitro. Kidney Int 2000; 58:1953-62.
34. Horiuchi T, Miyamoto K, Miyamoto S, Fujita M, Sano N, Minamiyama K, et al. Image analysis of remesothelialization following chemical wounding of cultured human peritoneal mesothelial cells: the role of hyaluronan synthesis. Kidney Int 2003; 64:2280-90.
35. Rosengren BI, Carlsson O, Rippe B. Hyaluronan and peritoneal ultrafiltration: a test of the "filter-cake" hypothesis. Am J Kidney Dis 2001; 37:1277-85.
36. Tamura M, Osajima A, Nakayamada S, Anai H, Kabashima N, Kanegae K, et al. High glucose levels inhibit focal adhesion kinase-mediated wound healing of rat peritoneal mesothelial cells. Kidney Int 2003; 63:722-31.
37. Witowski J, Wisniewska J, Korybalska K, Bender TO, Breborowicz A, Gahl GM, et al. Prolonged exposure to lucose degradation products impairs viability and function of human peritoneal mesothelial cells. J Am Soc Nephrol 2001; 12:2434-41.
38. Bajo MA, Selgas R, Castro MA, del Peso G, Diaz C, Sánchez-Tomero JA, et al. Icodextrin effluent leads to a greater proliferation than glucose effluent of human mesothelial cells studied ex vivo. Perit Dial Int 2000; 20:742-7.
39. Zareie M, van Lambalgen AA, ter Wee PM, Hekking LH, Keuning ED, Schadee-Eestermans IL, et al. Better preservation of the peritoneum in rats exposed to amino acid-based peritoneal dialysis fluid. Perit Dial Int 2005; 25:58-67.
40. Quagliaro L, Piconi L, Assaloni R, Martinelli L, Motz E, Ceriello A. Intermittent high glucose enhances apoptosis related to oxidative stress in human umbilical vein endothelial cells: the role of protein kinaseC and NAD(P) H-oxidase activation. Diabetes 2003; 52:2795-804.
41. Parikova A, Zweers MM, Struijk DG, Krediet RT. Peritoneal effluent markers of inflammation in patients treated with icodextrin-based and glucose-based dialysis solutions. Adv Perit Dial 2003; 19:186-90.
42. Martikainen TA, Teppo AM, Grönhagen-Riska C, Ekstrand AV. Glucose-free dialysis solutions: inductors of inflammation or preservers of peritoneal membrane? Perit Dial Int 2005; 25:453-60.
43. Posthuma N, ter Wee PM, Verbrugh HA, Oe PL, Peers E, Sayers J, et al. Icodextrin instead of glucose during the daytime dwell in CCPD increases ultrafiltration and 24-h dialysate creatinine clearance. Nephrol Dial Transplant 1997; 12:550-3.
44. Moriishi M, Kawanishi H, Watanabe H, Tsuchiya S. Correlation between peritoneal permeability and ultrafiltration volume with icodextrin-based peritoneal dialysis solution. Adv Perit Dial 2004; 20:166-9.